AMGEN, INC. for AMGEN INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 22, 2019 | $2,200,000 | Replaced |
| 2nd Quarter - Amendment | Jul 20, 2022 | $2,200,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
United States-Mexico-Canada Trade Agreement, no specific bill.
| Lobbyist | Covered position, as disclosed |
|---|---|
| VICTORIA BLATTER | — |
| L NICOLE CURRIE | — |
| JESSE KERNS | — |
| JORDAN LYNN LAYSON | — |
| HOWARD MOON | — |
| WILLIAM O'BRIEN | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
Taxation/Internal Revenue Code TAX
International Tax issues including: H.R.1: An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for the fiscal year Puerto Rico Tax Incentives
| Lobbyist | Covered position, as disclosed |
|---|---|
| L NICOLE CURRIE | — |
Copyright/Patent/Trademark CPT
S. 974 CREATES Act of 2017 S. 124 Preserve Access to Affordable Generics Act Issues related to drug patents and exclusivities (no bill) H.R. 1520, Purple Book Continuity Act of 2019 H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019 S. 1224, The Stop STALLING Act S. 1416, The Affordable Prescriptions for Patients Act, on product hopping and patent thicketing
| Lobbyist | Covered position, as disclosed |
|---|---|
| VICTORIA BLATTER | — |
| L NICOLE CURRIE | — |
| JESSE KERNS | — |
| JORDAN LYNN LAYSON | — |
| REBECCA MANDELL | — |
| HOWARD MOON | — |
| WILLIAM O'BRIEN | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
Health Issues HCR
Biosimilars, no specific bill Prescription drug value issues, no specific bill S. 469 Affordable and Safe Prescription Drug Importation Act H.R. 1245 Affordable and Safe Prescription Drug Importation Act 340B Protecting Access for the Underserved and Safety-Net Entities (340B PAUSE Act). FDA issues, no specific bill S.3158 Labor, Health and Human Services Appropriations Act (Senate Report 115-289) Issues related to International Pricing Index (IPI), no specific bill S. 551 Recovering Excessive Funds for Unused and Needless Drugs Act S. 657 Drug Price Transparency Act S. 658 Accelerated Drug Approval for Prescription Therapies Act S. 660 Efficiency and Transparency in Petitions Act S. 1895, Lower Health Care Costs Act (S. 1895), a comprehensive bill designed to improve healthcare transparency and reduce healthcare costs, including prescription drugs S. 1391, Fair Accountability and Innovative Research (FAIR) Drug Pricing Act (S. 1391) H.R. 1499, Protecting Consumer Access Generic Drugs Act H.R. 1344, Competitive Deals Resulting in Unleashed Generics and Savings (DRUGS) Act S. 1169, Ensuring Timely Access to Generics Act S. 1617, Second Look at Drug Patents Act H.R. 1520, Purple Book Continuity Act S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act S. 977, Transparent Drug Pricing Act S. 102, Prescription Drug Price Relief Act S. 637, Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act S. 659, Biologic Patent Transparency Act H.R. 1503, Orange Book Transparency Act H.R. 2296, Fair Accountability and Innovative Research (FAIR) Drug Pricing Act S. 1664, Prescription Drug Price Reporting Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| VICTORIA BLATTER | — |
| L NICOLE CURRIE | — |
| RUTH HOFFMAN | — |
| JESSE KERNS | — |
| JORDAN LYNN LAYSON New | — |
| REBECCA MANDELL | — |
| HOWARD MOON | — |
| WILLIAM O'BRIEN | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
Medicare/Medicaid MMM
Medicare Part B coverage and reimbursement issues Coding and reimbursement for biologics/biosimilars HR 6505 - Medicare Negotiation and Competitive Licensing Act (Doggett compulsory licensing bill) Issues related to Part D coverage gap, no specific bill S. 1676 Chronic Kidney Disease Improvement in Research and Treatment Act; Transitional drug add-on payment (TDAPA), dialysis bundled payment system issues H.R. 6142 Reducing Drug Waste Act of 2018 Issues related to the 340b program, no specific bill Drug Price Transparency Bills: oHR 2296/S 1391 FAIR Drug Pricing Act oHR 2113 Prescription Drug STAR Act oHR 2069 SPIKE Act S 1416 Affordable Prescriptions for Patients Act Issues related to Direct to Consumer Advertisement S. 551, Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act H.R. 2087, Drug Price Transparency Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| VICTORIA BLATTER | — |
| L NICOLE CURRIE | — |
| RUTH HOFFMAN | — |
| JESSE KERNS | — |
| JORDAN LYNN LAYSON | — |
| REBECCA MANDELL | — |
| HOWARD MOON | — |
| WILLIAM O'BRIEN | — |
| GREGORY PORTNER | — |
| HELEN RHEE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.